Absence of Anti-Babesia microti antibody in commercial intravenous immunoglobulin (IVIG)
PLOS Neglected Tropical Diseases · 2024
DOI: 10.1371/journal.pntd.0012035 ↗Kurz gefasst
Fachartikel in der Zeitschrift PLOS Neglected Tropical Diseases, 2024. Verfasst von Julia Kostka und 5 weiteren Autor:innen. Beteiligte Einrichtung: Infectious Disease, UConn Health, Farmington, Connecticut, United States of America. Hauptthemen laut MEDLINE: Babesiosis, Babesia microti. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 25 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC0). Gefördert von: UCONN Health, The Llura A. Gund Laboratory for Vector- borne Disease Research, Gordon and Llura Gund Foundation (PJK).
Abstract (Originalsprache)
Background
Babesiosis is a worldwide emerging protozoan infection that is associated with a spectrum of disease severity from asymptomatic infection to severe organ damage and death. While effective treatment strategies are available, some immunocompromised patients experience severe acute and prolonged/relapsing illness due in part to an impaired host antibody response. Intravenous immunoglobulin (IVIG) has been used as an adjunctive therapy in some immunocompromised babesiosis patients, but its therapeutic effect is uncertain. We evaluated the presence of Babesia microti antibodies in commercial samples of IVIG. Methods/principle findings The presence of B . microti antibodies in commercial samples of IVIG were tested using an immunofluorescence assay. A subset of samples was then tested for B . microti antibodies using an enzyme linked immunosorbent assay. Out of 57 commercial IVIG samples tested using IFA, and 52 samples tested using ELISA, none were positive for B . microti antibodies.
Conclusions
Commercially available IVIG may not be of therapeutic benefit for babesiosis patients. Additional sampling of IVIG for B. microti antibody and a clinical trial of babesiosis patients given IVIG compared with controls would provide further insight into the use of IVIG for the treatment of babesiosis.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Infectious Disease, UConn Health, Farmington, Connecticut, United States of America.
- Pathology and Laboratory Medicine, UConn Health, Farmington, Connecticut, United States of America.
- Food and Drug Administration, Silver Spring, Maryland, United States of America.
- Pharmacy, UConn Health, Farmington, Connecticut, United States of America.
- Yale School of Public Health and Yale School of Medicine, New Haven, Connecticut, United States of America.
ORCID-Profile: Julia Kostka
Förderung
- UCONN Health
- The Llura A. Gund Laboratory for Vector- borne Disease Research
- Gordon and Llura Gund Foundation (PJK)
- FDA Intramural Research Program
- University of Connecticut Health Center
- U.S. Food and Drug Administration
Zitieren
APA
Kostka, J., Maharjan, A. S., Kumar, S., Hackenyos, D., Krause, P. J., & Dieckhaus, K. (2024). Absence of Anti-Babesia microti antibody in commercial intravenous immunoglobulin (IVIG). PLOS Neglected Tropical Diseases. https://doi.org/10.1371/journal.pntd.0012035
Vancouver
Kostka J, Maharjan AS, Kumar S, Hackenyos D, Krause PJ, Dieckhaus K. Absence of Anti-Babesia microti antibody in commercial intravenous immunoglobulin (IVIG). PLOS Neglected Tropical Diseases. 2024. doi:10.1371/journal.pntd.0012035
BibTeX
@article{Kostka2024,
author = {Kostka, Julia and Maharjan, Anu S and Kumar, Sanjai and Hackenyos, Douglas and Krause, Peter J and Dieckhaus, Kevin},
title = {Absence of Anti-Babesia microti antibody in commercial intravenous immunoglobulin (IVIG)},
journal = {PLOS Neglected Tropical Diseases},
year = {2024},
doi = {10.1371/journal.pntd.0012035}
}
EUVIMED